TY - JOUR AU - Faragó, Anna AU - Zvara, Ágnes AU - Tiszlavicz, László AU - Hunyadi-Gulyás Éva, Csilla AU - Darula, Zsuzsanna AU - Hegedűs, Zoltán AU - Szabó, Enikő AU - Surguta, Sára Eszter AU - Tóvári, József AU - Puskás, László AU - Szebeni, Gábor TI - Lectin-Based Immunophenotyping and Whole Proteomic Profiling of CT-26 Colon Carcinoma Murine Model. JF - INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES J2 - INT J MOL SCI VL - 25 PY - 2024 IS - 7 PG - 21 SN - 1661-6596 DO - 10.3390/ijms25074022 UR - https://m2.mtmt.hu/api/publication/34790193 ID - 34790193 N1 - * Megosztott szerzőség AB - A murine colorectal carcinoma (CRC) model was established. CT26 colon carcinoma cells were injected into BALB/c mice's spleen to study the primary tumor and the mechanisms of cell spread of colon cancer to the liver. The CRC was verified by the immunohistochemistry of Pan Cytokeratin and Vimentin expression. Immunophenotyping of leukocytes isolated from CRC-bearing BALB/c mice or healthy controls, such as CD19+ B cells, CD11+ myeloid cells, and CD3+ T cells, was carried out using fluorochrome-labeled lectins. The binding of six lectins to white blood cells, such as galectin-1 (Gal1), siglec-1 (Sig1), Sambucus nigra lectin (SNA), Aleuria aurantia lectin (AAL), Phytolacca americana lectin (PWM), and galectin-3 (Gal3), was assayed. Flow cytometric analysis of the splenocytes revealed the increased binding of SNA, and AAL to CD3 + T cells and CD11b myeloid cells; and increased siglec-1 and AAL binding to CD19 B cells of the tumor-bearing mice. The whole proteomic analysis of the established CRC-bearing liver and spleen versus healthy tissues identified differentially expressed proteins, characteristic of the primary or secondary CRC tissues. KEGG Gene Ontology bioinformatic analysis delineated the established murine CRC characteristic protein interaction networks, biological pathways, and cellular processes involved in CRC. Galectin-1 and S100A4 were identified as upregulated proteins in the primary and secondary CT26 tumor tissues, and these were previously reported to contribute to the poor prognosis of CRC patients. Modelling the development of liver colonization of CRC by the injection of CT26 cells into the spleen may facilitate the understanding of carcinogenesis in human CRC and contribute to the development of novel therapeutic strategies. LA - English DB - MTMT ER - TY - JOUR AU - Szabó, Enikő AU - Modok, Szabolcs AU - Rónaszéki, Benedek AU - Faragó, Anna AU - Gémes, Nikolett AU - Nagy, Lajos I. AU - Hackler, László AU - Farkas, Katalin AU - Neuperger, Patricia AU - Balog, József Ágoston AU - Balog, Attila AU - Puskás, László AU - Szebeni, Gábor TI - Comparison of humoral and cellular immune responses in hematologic diseases following completed vaccination protocol with BBIBP-CorV, or AZD1222, or BNT162b2 vaccines against SARS-CoV-2 JF - FRONTIERS IN MEDICINE J2 - FRONT MED VL - 10 PY - 2023 PG - 11 SN - 2296-858X DO - 10.3389/fmed.2023.1176168 UR - https://m2.mtmt.hu/api/publication/34069256 ID - 34069256 N1 - Funding Agency and Grant Number: National Research, Development, and Innovation Office (NKFI), Hungary [2020-1.1.6-JOVO-2021-00003, 142877 FK22, KFI_16-1-2017-0105]; KDP-2021 Program of the Ministry for Innovation and Technology from the source of the National Research, Development and Innovation Fund [C1764415]; Jnos Bolyai Research Scholarship of the Hungarian Academy of Sciences [BO/00582/22/8]; Ministry of Culture and Innovation; New National Excellence Program [NTP-NFTOE-21-B-0164] Funding text: This research was funded by the 2020-1.1.6-JOEVO-2021-00003 and 142877 FK22, KFI_16-1-2017-0105 grant from the National Research, Development, and Innovation Office (NKFI), Hungary. This work was supported by the UNKP-22-5-SZTE-535 New National Excellence Program for GS, and by the KDP-2021 Program for NG (C1764415) of the Ministry for Innovation and Technology from the source of the National Research, Development and Innovation Fund. This work was supported by the Janos Bolyai Research Scholarship of the Hungarian Academy of Sciences BO/00582/22/8 (GS). This manuscript was prepared with the professional support of SZTE AOK-KKA Hetenyi Geza Scholarship_5S726 (AB). This manuscript was prepared with the support of the National Young Talent Scholarship for ES (NTP-NFTOE-21-B-0164) by the Ministry of Culture and Innovation. LA - English DB - MTMT ER - TY - JOUR AU - Domokos, Apolka AU - Varga, Zsófia AU - Jambrovics, Károly AU - Caballero-Sánchez, Noemí AU - Szabó, Enikő AU - Nagy, Gergely AU - Scholtz, Beáta AU - Halasz, Laszlo AU - Váradi, Eszter Anna AU - Bene, Krisztián AU - Mazlo, Anett AU - Bacsi, Attila AU - Jeney, Viktoria AU - Szebeni, Gábor AU - Nagy, László AU - Czimmerer, Zsolt TI - The transcriptional control of the VEGFA-VEGFR1 (FLT1) axis in alternatively polarized murine and human macrophages JF - FRONTIERS IN IMMUNOLOGY J2 - FRONT IMMUNOL VL - 14 PY - 2023 SN - 1664-3224 DO - 10.3389/fimmu.2023.1168635 UR - https://m2.mtmt.hu/api/publication/33805004 ID - 33805004 N1 - Funding Agency and Grant Number: Hungarian National Research, Development, and Innovation Office [FK132185, 2020-1.1.6-JOVO-2021-00003, 142877 FK22, K131535]; New National Excellence Program of the Ministry for Innovation and Technology [UNKP-22-5-SZTE-549]; Janos Bolyai Research Scholarship of the Hungarian Academy of Sciences [BO/00594/22/8]; National Research, Development, and Innovation Office [PD142930, PD135102]; Hungarian Academy of Sciences (MTA-DE Lendulet Vascular Pathophysiology Research Group [96050] Funding text: Funding ZC was supported by Hungarian National Research, Development, and Innovation Office (FK132185), and by the New National Excellence Program of the Ministry for Innovation and Technology (UNKP-22-5-SZTE-549), and by the Janos Bolyai Research Scholarship of the Hungarian Academy of Sciences BO/00594/22/8. GS was supported by the 2020-1.1.6-JOVO-2021-00003 and 142877 FK22 grant from the Hungarian National Research, Development, and Innovation Office and by the UNKP-22-5 -SZTE-535 New National Excellence Program of the Ministry for Innovation and Technology and by the Janos Bolyai Research Scholarship of the Hungarian Academy of Sciences BO/00582/22/8. ES was supported by the 2020-1.1.6-JOVO-2021-00003. AM and GN were supported by National Research, Development, and Innovation Office (PD142930 to AM and PD135102 to GN) VJ was funded by the Hungarian National Research, Development and Innovation Office (K131535) and the Hungarian Academy of Sciences (MTA-DE Lendulet Vascular Pathophysiology Research Group, grant number 96050). LA - English DB - MTMT ER - TY - JOUR AU - Gémes, Nikolett AU - Makra, Zsófia AU - Neuperger, Patricia AU - Szabó, Enikő AU - Balog, József Ágoston AU - Flink, Lili Borbála AU - Kari, Beáta AU - Hackler, László AU - Puskás, László AU - Kanizsai, Iván AU - Szebeni, Gábor TI - A cytotoxic survey on 2-amino-1H-imidazol based synthetic marine sponge alkaloid analogues JF - DRUG DEVELOPMENT RESEARCH J2 - DRUG DEVELOP RES VL - 83 PY - 2022 IS - 8 SP - 1906 EP - 1922 PG - 17 SN - 0272-4391 DO - 10.1002/ddr.22006 UR - https://m2.mtmt.hu/api/publication/33211172 ID - 33211172 N1 - Funding Agency and Grant Number: National Research, Development, and Innovation Office (NKFI), Hungary [2020-1.1.6-JOVO-2021-00003, 142877 FK22]; New National Excellence Program of the Ministry for Innovation and Technology from the source of the National Research, Development and Innovation Fund [UNKP-22-5 -SZTE-535]; [BO/00582/22/8] Funding text: This research was funded by the 2020-1.1.6-JOVO-2021-00003 and 142877 FK22 (GJS) grant from the National Research, Development, and Innovation Office (NKFI), Hungary. This work was supported by the UNKP-22-5 -SZTE-535 (GJS) New National Excellence Program of the Ministry for Innovation and Technology from the source of the National Research, Development and Innovation Fund. This work was supported by the Janos Bolyai Research Scholarship of the Hungarian Academy of Sciences BO/00582/22/8 (GJS). AB - Here, we describe the synthesis and biologic activity evaluation of 20 novel synthetic marine sponge alkaloid analogues with 2-amino-1H-imidazol (2-AI) core. Cytotoxicity was tested on murine 4T1 breast cancer, A549 human lung cancer, and HL-60 human myeloid leukemia cells by the resazurin assay. A total of 18 of 20 compounds showed cytotoxic effect on the cancer cell lines with different potential. Viability of healthy human fibroblasts and peripheral blood mononuclear cells upon treatment was less hampered compared to cancer cell lines supporting tumor cell specific cytotoxicity of our compounds. The most cytotoxic compounds resulted the following IC50 values 28: 2.91 µM on HL-60 cells, and 29: 3.1 µM on 4T1 cells. The A549 cells were less sensitive to the treatments with IC50 15 µM for both 28 and 29. Flow cytometry demonstrated the apoptotic effect of the most active seven compounds inducing phosphatidylserine exposure and sub-G1 fragmentation of nuclear DNA. Cell cycle arrest was also observed. Four compounds caused depolarization of the mitochondrial membrane potential as an early event of apoptosis. Two lead compounds inhibited tumor growth in vivo in the 4T1 triple negative breast cancer and A549 human lung adenocarcinoma xenograft models. Novel marine sponge alkaloid analogues are demonstrated as potential anticancer agents for further development. LA - English DB - MTMT ER - TY - JOUR AU - Honfi, Dániel György AU - Gémes, Nikolett AU - Szabó, Enikő AU - Neuperger, Patricia AU - Balog, József Ágoston AU - Nagy, Lajos I. AU - Toldi, Gergely AU - Puskás, László AU - Szebeni, Gábor AU - Balog, Attila TI - Comparison of Homologous and Heterologous Booster SARS-CoV-2 Vaccination in Autoimmune Rheumatic and Musculoskeletal Patients JF - INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES J2 - INT J MOL SCI VL - 23 PY - 2022 IS - 19 PG - 15 SN - 1661-6596 DO - 10.3390/ijms231911411 UR - https://m2.mtmt.hu/api/publication/33115577 ID - 33115577 N1 - Funding Agency and Grant Number: National Research, Development, and Innovation Office (NKFIH), Hungary [2020-1.1.6-JOVO -2021-00003, 142877 FK22OTKA]; SZTE AOK-KKA Hetenyi 2020 grant; Ministry of Innovation and Technology - National Research, Development, and Innovation Fund [C1764415]; Janos Bolyai Research Scholarship of the Hungarian Academy of Sciences [BO/00582/22/8] Funding text: This research was funded by the grants 2020-1.1.6-JOVO -2021-00003 and 142877 FK22OTKA (GJS) from the National Research, Development, and Innovation Office (NKFIH), Hungary. This work was supported by the SZTE AOK-KKA Hetenyi 2020 grant (AB). This manuscript was prepared with the professional support of the doctoral student scholarship program of the Ministry of Innovation and Technology, financed by the National Research, Development, and Innovation Fund for NG (C1764415). This paper was supported by the Janos Bolyai Research Scholarship of the Hungarian Academy of Sciences (BO/00582/22/8 for GJS). AB - Vaccination against SARS-CoV-2 to prevent COVID-19 is highly recommended for immunocompromised patients with autoimmune rheumatic and musculoskeletal diseases (aiRMDs). Little is known about the effect of booster vaccination or infection followed by previously completed two-dose vaccination in aiRMDs. We determined neutralizing anti-SARS-CoV-2 antibody levels and applied flow cytometric immunophenotyping to quantify the SARS-CoV-2 reactive B- and T-cell mediated immunity in aiRMDs receiving homologous or heterologous boosters or acquired infection following vaccination. Patients receiving a heterologous booster had a higher proportion of IgM+ SARS-CoV-2 S+ CD19+CD27+ peripheral memory B-cells in comparison to those who acquired infection. Biologic therapy decreased the number of S+CD19+; S+CD19+CD27+IgG+; and S+CD19+CD27+IgM+ B-cells. The response rate to a booster event in cellular immunity was the highest in the S-, M-, and N-reactive CD4+CD40L+ T-cell subset. Patients with a disease duration of more than 10 years had higher proportions of CD8+TNF-α+ and CD8+IFN-γ+ T-cells in comparison to patients who were diagnosed less than 10 years ago. We detected neutralizing antibodies, S+ reactive peripheral memory B-cells, and five S-, M-, and N-reactive T-cells subsets in our patient cohort showing the importance of booster events. Biologic therapy and <10 years disease duration may confound anti-SARS-CoV-2 specific immunity in aiRMDs. LA - English DB - MTMT ER - TY - JOUR AU - Hetényi, Anasztázia AU - Szabó, Enikő AU - Imre, Norbert AU - Nath Bhaumik, Kaushik AU - Tököli, Attila AU - Füzesi, Tamás AU - Hollandi, Réka AU - Horváth, Péter AU - Czibula, Ágnes AU - Monostori, Éva AU - Deli, Mária Anna AU - Martinek, Tamás TI - α/β-Peptides as Nanomolar Triggers of Lipid Raft-Mediated Endocytosis through GM1 Ganglioside Recognition JF - PHARMACEUTICS J2 - PHARMACEUTICS VL - 14 PY - 2022 IS - 3 PG - 11 SN - 1999-4923 DO - 10.3390/pharmaceutics14030580 UR - https://m2.mtmt.hu/api/publication/32733913 ID - 32733913 N1 - Funding Agency and Grant Number: National Research, Development and Innovation Office of HungaryNational Research, Development & Innovation Office (NRDIO) - Hungary [GINOP-2.2.1-15-2016-00007]; Hungarian Ministry of Innovation and Technology [TUDFO/47138-1/2019-ITM]; Hungarian National Brain Research Program (MTA-SE-NAP B-BIOMAG); Hungarian Academy of Sciences LENDULET-FoldamerHungarian Academy of Sciences; NKFINational Research, Development & Innovation Office (NRDIO) - Hungary [K134754]; Finnish TEKES FiDiPro Fellow Grant [40294/13]; Hungarian Academy of Sciences LENDULET-BiomagHungarian Academy of Sciences; Ministry of Innovation and Technology of Hungary through the National Research, Development and Innovation Fund [TKP2021-EGA-32] Funding text: This research was funded by the National Research, Development and Innovation Office of Hungary, grant number GINOP-2.2.1-15-2016-00007, the Hungarian Ministry of Innovation and Technology, TUDFO/47138-1/2019-ITM, and the Hungarian National Brain Research Program (MTA-SE-NAP B-BIOMAG). T.A.M. acknowledges support from the Hungarian Academy of Sciences LENDULET-Foldamer, and NKFI K134754. P.H. acknowledges support from the Finnish TEKES FiDiPro Fellow Grant 40294/13, and the Hungarian Academy of Sciences LENDULET-Biomag. Support by the Ministry of Innovation and Technology of Hungary through the National Research, Development and Innovation Fund (TKP2021-EGA-32) is acknowledged. AB - Cell delivery of therapeutic macromolecules and nanoparticles is a critical drug development challenge. Translocation through lipid raft-mediated endocytic mechanisms is being sought, as it can avoid rapid lysosomal degradation. Here, we present a set of short alpha/beta-peptide tags with high affinity to the lipid raft-associated ganglioside GM1. These sequences induce effective internalization of the attached immunoglobulin cargo. The structural requirements of the GM1-peptide interaction are presented, and the importance of the membrane components are shown. The results contribute to the development of a receptor-based cell delivery platform. LA - English DB - MTMT ER - TY - JOUR AU - Szebeni, Gábor AU - Gémes, Nikolett AU - Honfi, Dániel György AU - Szabó, Enikő AU - Neuperger, Patricia AU - Balog, József Ágoston AU - Nagy, LI AU - Szekanecz, Zoltán AU - Puskás, László AU - Toldi, Gergely AU - Balog, Attila TI - Humoral and cellular immunogenicity and safety of five different SARS-CoV-2 vaccines in patients with autoimmune rheumatic and musculoskeletal diseases in remission or with low disease activity and in healthy controls: a single center study JF - FRONTIERS IN IMMUNOLOGY J2 - FRONT IMMUNOL VL - 13 PY - 2022 PG - 11 SN - 1664-3224 DO - 10.3389/fimmu.2022.846248 UR - https://m2.mtmt.hu/api/publication/32728646 ID - 32728646 N1 - Funding Agency and Grant Number: National Research, Development, and Innovation Office (NKFIH), Hungary [2020-1.1.6-JOVO-2021-00003]; National Research, Development, and Innovation Fund [KDP-17-4/PALY-2021, 1000464] Funding text: This study was supported by the grant 2020-1.1.6-JOVO-2021-00003 from the National Research, Development, and Innovation Office (NKFIH), Hungary. This manuscript was prepared with the professional support of the doctoral student scholarship program of the Ministry of Innovation and Technology, financed by the National Research, Development, and Innovation Fund for JB (KDP-17-4/PALY-2021, 1000464). AB - Background: Vaccine-induced immunity is essential for controlling the COVID-19 pandemic. Data on humoral and cellular immunogenicity and safety of different SARS-CoV-2 vaccines in patients with autoimmune rheumatic and musculoskeletal diseases (RMDs) are limited. Methods: A single center observational study evaluated the immunogenicity and safety of the two-dose regimen of the BBIBP-CorV inactivated, Gam-COVID-Vac and AZD1222 adenovirus-based, and BNT162b2 and mRNA-1273 mRNA-based vaccines in patients with RMDs (n = 89) compared with healthy controls (n = 74). Neutralizing anti-RBD (receptor binding domain) specific antibodies and SARS-CoV-2 specific T-cell response were measured one and four months after the second vaccine dose in parallel with vaccination efficacy and safety. Results: Disease-specific comparison showed that antibody response at four months was higher in spondylarthropathies compared to rheumatoid arthritis and autoimmune RMDs. Risk factors for reduced immunogenicity included longer disease duration, positive immunoserological profile and anti-CD20 therapy of patients. The rate of positive anti-RBD antibody response for healthy controls versus patients after 4 months post vaccination was 69% vs. 55% for the inactivated viral vaccine BBIBP-CorV, 97% vs. 53% for the pooled data of adenovirus vector-based vaccines Gam-COVID-Vac and AZD1222, or 100% vs. 81% for the pooled data of mRNA vaccines BNT162b2 and mRNA-1273, respectively. Patients who received the Gam-COVID-Vac or mRNA-1273 vaccines had a higher proportion of TNF-alpha producing CD4+ T-cells upon SARS-CoV-2 antigen stimulation compared to the inactivated viral vaccine. Conclusion: All five investigated vaccines were immunogenic in the majority of patients and healthy controls with variable antibody and T-cell response and an acceptable safety profile. LA - English DB - MTMT ER - TY - JOUR AU - Hetényi, Anasztázia AU - Imre, Norbert AU - Szabó, Enikő AU - Bodnár, Brigitta AU - Szkalisity, Ábel AU - Gróf, Ilona AU - Bocsik, Alexandra AU - Deli, Mária Anna AU - Horváth, Péter AU - Czibula, Ágnes AU - Monostori, Éva AU - Martinek, Tamás TI - Fehérje méretű molekulák humán sejtekbe juttatása lipid-raft mediált endocitózissal JF - BIOKÉMIA: A MAGYAR BIOKÉMIAI EGYESÜLET FOLYÓIRATA J2 - BIOKÉMIA VL - 45 PY - 2021 IS - 4 SP - 67 EP - 83 PG - 17 SN - 0133-8455 UR - https://m2.mtmt.hu/api/publication/32570862 ID - 32570862 N1 - Nincs jelölve levelező szerzőség a közleményen. (BÉ SZTE admin5) LA - Hungarian DB - MTMT ER - TY - JOUR AU - Imre, Norbert AU - Hetényi, Anasztázia AU - Szabó, Enikő AU - Bodnár, Brigitta AU - Szkalisity, Ábel AU - Gróf, Ilona AU - Bocsik, Alexandra AU - Deli, Mária Anna AU - Horváth, Péter AU - Czibula, Ágnes AU - Monostori, Éva AU - Martinek, Tamás TI - Routing Nanomolar Protein Cargoes to Lipid Raft‐Mediated/Caveolar Endocytosis through a Ganglioside GM1‐Specific Recognition Tag JF - ADVANCED SCIENCE J2 - ADV SCI VL - 7 PY - 2020 IS - 4 PG - 10 SN - 2198-3844 DO - 10.1002/advs.201902621 UR - https://m2.mtmt.hu/api/publication/31126947 ID - 31126947 N1 - Funding text: This research was funded by the National Research, Development and Innovation Office of Hungary, grant number GINOP-2.2.1-15-2016-00007, the Hungarian Ministry of Innovation and Technology, TUDFO/47138-1/2019-ITM, and Hungarian National Brain Research Program (MTA-SE-NAP B-BIOMAG). T.A.M. acknowledges support from the Hungarian Academy of Sciences LENDULET-Foldamer. P.H. acknowledges support from the Finnish TEKES FiDiPro Fellow Grant 40294/13, the Hungarian Academy of Sciences LENDULET-Biomag. LA - English DB - MTMT ER - TY - JOUR AU - Szabó, Enikő AU - Hornung, Ákos AU - Monostori, Éva AU - Bocskai, Márta AU - Czibula, Ágnes AU - Kovács, László TI - Altered Cell Surface N-Glycosylation of Resting and Activated T Cells in Systemic Lupus Erythematosus JF - INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES J2 - INT J MOL SCI VL - 20 PY - 2019 IS - 18 PG - 14 SN - 1661-6596 DO - 10.3390/ijms20184455 UR - https://m2.mtmt.hu/api/publication/30802849 ID - 30802849 N1 - Institute of Genetics, Biological Research Centre of the Hungarian Academy of Sciences, Szeged, 6726, Hungary Department of Rheumatology and Immunology, Faculty of Medicine, University of Szeged, Szeged, 6725, Hungary Export Date: 29 November 2019 Correspondence Address: Czibula, Á.; Institute of Genetics, Biological Research Centre of the Hungarian Academy of SciencesHungary; email: czibula.agnes@brc.hu Chemicals/CAS: galectin 1, 258495-34-0; sialidase, 9001-67-6; sialyltransferase, 9075-81-4 Institute of Genetics, Biological Research Centre of the Hungarian Academy of Sciences, Szeged, 6726, Hungary Department of Rheumatology and Immunology, Faculty of Medicine, University of Szeged, Szeged, 6725, Hungary Export Date: 2 December 2019 Correspondence Address: Czibula, Á.; Institute of Genetics, Biological Research Centre of the Hungarian Academy of SciencesHungary; email: czibula.agnes@brc.hu Chemicals/CAS: galectin 1, 258495-34-0; sialidase, 9001-67-6; sialyltransferase, 9075-81-4 LA - English DB - MTMT ER -